secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2026-08-06T11:33:24+00:00
Accession:  0001062822-26-000112
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q2 net loss $31.8M; SONATA-HCM enrollment complete; ZYNQUISTA NDA resubmission Q4 2026
--------------------------------------------------------------------------------

- Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025; total revenue $0.7M (all INPEFA) vs $28.9M (incl $27.6M licensing) YoY.
- Cash and investments $190.6M at June 30, 2026, up from $125.2M at Dec 31, 2025; $100M Hercules loan facility entered, $55M drawn.
- SONATA-HCM Phase 3 enrollment completed (exceeded 500 patients); top-line data expected Q1 2027.
- ZYNQUISTA NDA resubmission for T1D expected Q4 2026, pending STENO1 safety data.
- LX9851 Phase 1 by Novo Nordisk ongoing; Lexicon eligible for up to $1B milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/0001062822-26-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/lxrx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001062822-26-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer